Illumina faces record European Union fine over Grail deal next week – report

New York

clear sky

Social Media

Light

Dark

Sundry Images/iStock Editorial by way of Getty Photos Illumina (NASDAQ:ILMN) faces a document tremendous from the European Union as early as subsequent week after finishing its buy of cancer-screening firm Grail with out the antitrust regulator's approval. The tremendous could also be as a lot as $453 million, or 10% of the corporate's income, in …

Illumina headquarters in Silicon Valley — Sundry Images/iStock Editorial by way of Getty Photos

Illumina (NASDAQ:ILMN) faces a document tremendous from the European Union as early as subsequent week after finishing its buy of cancer-screening firm Grail with out the antitrust regulator’s approval.

The tremendous could also be as a lot as $453 million, or 10% of the corporate’s income, in accordance to a Monetary Occasions report on Tuesday, which cited individuals accustomed to the matter.

“We disagree that the fee has jurisdiction to evaluation the Grail transaction in addition to with the premise of the fee imposing a tremendous,” Illumina instructed the FT in a press release. “Now we have appealed the EU’s jurisdiction and can enchantment any resolution imposing a tremendous.”

Reuters first reported concerning the potential EU tremendous in January.

Final month, Francis deSouza , the previous CEO of Illumina, resigned from his place. Activist Carl Icahn had been calling for the CEO’s removing, citing the corporate’s resolution to amass most cancers take a look at developer Grail regardless of regulatory pushback.